An amended Schedule 13G (Amendment No. 5) was filed with the SEC disclosing that a group of related entities led by Invus Public Equities, L.P. and individual filer Raymond Debbane held an aggregate beneficial ownership position in Silence Therapeutics plc as of September 30, 2026.

Key Highlights

  • Raymond Debbane's aggregate position: 8,663,601 ordinary shares (including ADS-equivalent shares), representing 4.6% of the class, according to the filing.
  • Invus Public Equities, L.P. position: 7,591,233 ordinary shares, equal to 4.1% of the class, held via 2,530,411 ADSs each representing three ordinary shares.
  • Avicenna Life Sci Master Fund LP position: 1,072,368 ordinary shares, equal to 0.6% of the class, held via 357,456 ADSs.
  • No shared voting or dispositive power: All reporting persons reported 0 shared voting power and 0 shared dispositive power.
  • Triggering event date: September 30, 2026, identified in the filing as the date of the event requiring the statement.
  • Security described: Ordinary shares with a nominal value of 0.05 GBP per share, CUSIP 82686Q101.

Invus Group and Avicenna Fund Disclose Combined Holdings in Silence Therapeutics

According to the Schedule 13G Amendment No. 5, eight reporting persons affiliated with the Invus organization filed a joint beneficial ownership disclosure for Silence Therapeutics plc (NASDAQ:SLN). The filing identifies the triggering event date as September 30, 2026, and was submitted to reflect the group's current holdings in the company's ordinary shares, which trade in ADS form on the NASDAQ exchange.

The filing reports that Invus Public Equities, L.P., a Bermuda limited partnership, holds 2,530,411 ADSs. Each ADS represents three ordinary shares with a nominal value of 0.05 GBP per share, bringing Invus Public Equities' equivalent ordinary share count to 7,591,233, or 4.1% of the class. The same share count and percentage are attributed to affiliated entities Invus Public Equities Advisors, LLC, Invus Global Management, LLC, and Siren, L.L.C., all of which are organized in Delaware and share the same New York address, according to the filing.

Separately, Avicenna Life Sci Master Fund LP, a Cayman Islands limited partnership, holds 357,456 ADSs, equivalent to 1,072,368 ordinary shares, or 0.6% of the class. Its affiliated entities, Avicenna Life Sci Master GP LLC and Ulys, L.L.C., report the same figures. Individual filer Raymond Debbane, whose citizenship is listed as Panama, is attributed the combined total of 8,663,601 ordinary shares, representing 4.6% of the class, reflecting the aggregation of both the Invus Public Equities and Avicenna Fund positions, as described in the filing's comment fields.

What Was Disclosed

The filing is Amendment No. 5 to a Schedule 13G covering beneficial ownership of Silence Therapeutics plc ordinary shares as of September 30, 2026. Eight related reporting persons, including Invus Public Equities, L.P. and Raymond Debbane, disclosed sole voting and dispositive power over shares held through ADSs.